Literature DB >> 10583376

Solution structure of a new hypothalamic neuropeptide, human hypocretin-2/orexin-B.

J H Lee1, E Bang, K J Chae, J Y Kim, D W Lee, W Lee.   

Abstract

Orexin-A and orexin-B (also called hypocretin-1 and hypocretin-2, respectively) are novel hypothalamic neuropeptides encoded by a single mRNA transcript; they stimulate food intake. We have determined the three-dimensional solution structure of human hypocretin-2/orexin-B using two-dimensional 1H-NMR data and dynamical simulated annealing calculations. On the basis of NOEs, 3JHNalpha coupling constants and hydrogen-deuterium exchange rates together with chemical shift indices, human hypocretin-2/orexin-B was deduced to consist of two alpha-helices connected with a short linker in both H2O and 30% trifluoroethanol solutions. The helical axis of helix I is oriented about 60-80 degrees relative to helix II. Hybrid distance geometry and simulated-annealing protocols were used to generate an ensemble of 30 structures with no constraint violations greater than 0.03 nm for distances and 3 degrees for angles. In addition, human hypocretin-2/orexin-B shares a similar secondary-structural motif with human neuropeptide Y. This result can form the basis for further study on ligand-receptor recognition of human orexin receptors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10583376     DOI: 10.1046/j.1432-1327.1999.00911.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  16 in total

Review 1.  Orexin receptors: pharmacology and therapeutic opportunities.

Authors:  Thomas E Scammell; Christopher J Winrow
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011       Impact factor: 13.820

Review 2.  Hypocretins and the neurobiology of sleep-wake mechanisms.

Authors:  Luis de Lecea
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

Review 3.  Challenges in the development of therapeutics for narcolepsy.

Authors:  Sarah Wurts Black; Akihiro Yamanaka; Thomas S Kilduff
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

4.  Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors.

Authors:  Jie Yin; Kerim Babaoglu; Chad A Brautigam; Lindsay Clark; Zhenhua Shao; Thomas H Scheuermann; Charles M Harrell; Anthony L Gotter; Anthony J Roecker; Christopher J Winrow; John J Renger; Paul J Coleman; Daniel M Rosenbaum
Journal:  Nat Struct Mol Biol       Date:  2016-03-07       Impact factor: 15.369

5.  Crucial role of the orexin-B C-terminus in the induction of OX1 receptor-mediated apoptosis: analysis by alanine scanning, molecular modelling and site-directed mutagenesis.

Authors:  Pascal Nicole; Pierre Couvineau; Nadege Jamin; Thierry Voisin; Alain Couvineau
Journal:  Br J Pharmacol       Date:  2015-09-30       Impact factor: 8.739

6.  Truncated Orexin Peptides: Structure-Activity Relationship Studies.

Authors:  Nadezhda A German; Ann M Decker; Brian P Gilmour; Brian F Thomas; Yanan Zhang
Journal:  ACS Med Chem Lett       Date:  2013-12-12       Impact factor: 4.345

7.  Modeling of the OX1R-orexin-A complex suggests two alternative binding modes.

Authors:  Lasse Karhu; Ainoleena Turku; Henri Xhaard
Journal:  BMC Struct Biol       Date:  2015-05-09

8.  CD4+ T-Cell Reactivity to Orexin/Hypocretin in Patients With Narcolepsy Type 1.

Authors:  Melanie Ramberger; Birgit Högl; Ambra Stefani; Thomas Mitterling; Markus Reindl; Andreas Lutterotti
Journal:  Sleep       Date:  2017-03-01       Impact factor: 5.849

9.  Hypocretin/Orexin neuropeptides: participation in the control of sleep-wakefulness cycle and energy homeostasis.

Authors:  A Nuñez; M L Rodrigo-Angulo; I De Andrés; M Garzón
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

10.  Toward an understanding of agonist binding to human Orexin-1 and Orexin-2 receptors with G-protein-coupled receptor modeling and site-directed mutagenesis.

Authors:  Alexander Heifetz; Oliver Barker; G Benjamin Morris; Richard J Law; Mark Slack; Philip C Biggin
Journal:  Biochemistry       Date:  2013-11-08       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.